Agios Pharmaceuticals, Inc. (AGIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149899,
    "name": "Agios Pharmaceuticals, Inc.",
    "stock_name": "Agios Pharmaceuticals, Inc.",
    "full_name": "Agios Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/agios-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "27.42",
    "chg": 0.44,
    "chgp": "1.63%",
    "dir": 1,
    "prev_price": "26.98",
    "mcapval": "2,690.76",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US00847X1046",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.45 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/agios-pharmaceuticals-inc-1149899-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Agios Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-agios-pharmaceuticals-inc-overvalued-or-undervalued-3637605",
        "imagepath": "",
        "date": "2025-10-21 12:05:35",
        "description": "As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has changed from very attractive to attractive, indicating a shift in market perception. The company appears to be undervalued, with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA ratio of -3.81, which suggests that the stock may be trading at a significant discount relative to its earnings potential. \n\nIn comparison to its peers, Agios has a lower P/E ratio than PTC Therapeutics, Inc. at 5.85 and Crinetics Pharmaceuticals, Inc. at -8.95, indicating that it is relatively cheaper in terms of earnings. The company's return performance shows a 1-week return of 4.24% compared to the S&P 500's 1.70%, and a year-to-date return of 28.82% against the S&P 500's 13.30%, which reinforces the notion that the stock may be undervalued...."
      },
      {
        "title": "Agios Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/agios-pharmaceuticals-valuation-grade-downgraded-from-very-attractive-to-attractive-3640437",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AgiosPharmaceut_valuationdot_3640437.png",
        "date": "2025-10-20 15:22:08",
        "description": "Agios Pharmaceuticals, Inc. has adjusted its valuation, showcasing a low P/E ratio of 4 and a price-to-book value of 1.73. Despite a challenging year, the company has demonstrated resilience with a year-to-date return of 28.82%, outperforming the S&P 500, and maintains a competitive PEG ratio of 0.01."
      },
      {
        "title": "Is Agios Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-agios-pharmaceuticals-inc-overvalued-or-undervalued-3634474",
        "imagepath": "",
        "date": "2025-10-20 12:23:01",
        "description": "As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. Based on the current metrics, the company appears to be undervalued, particularly highlighted by a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81. \n\nIn comparison to its peers, Agios Pharmaceuticals has a significantly lower P/E ratio than PTC Therapeutics, Inc., which stands at 5.85, and a much lower EV to EBITDA than Supernus Pharmaceuticals, Inc., which is at 13.83. While Agios has shown strong short-term performance, with a 1-month return of 16.23% compared to the S&P 500's 0.96%, its longer-term returns have lagged, particularly over the past three years, where it returned 50.37% versus the S&P 500's 81.19%. Overall, the valuation metrics suggest that Agios Pharmaceuticals is currently undervalued relative to its ..."
      },
      {
        "title": "Is Agios Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-agios-pharmaceuticals-inc-overvalued-or-undervalued-3632012",
        "imagepath": "",
        "date": "2025-10-19 12:00:35",
        "description": "As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has moved from very attractive to attractive. The company appears to be undervalued based on its current metrics, particularly with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81. In comparison to peers, PTC Therapeutics, Inc. has a P/E of 5.85, while Supernus Pharmaceuticals, Inc. is considered expensive with a P/E of 37.12.\n\nDespite the recent downgrade in valuation grade, Agios Pharmaceuticals has shown strong short-term performance, with a year-to-date return of 28.82% compared to the S&P 500's 13.30%. However, over the longer term, the stock has underperformed the index, with a 1-year return of -4.10% versus the S&P 500's 14.08%. Overall, the current valuation metrics suggest that Agios Pharmaceuticals is positioned as an attractive investment opportunity...."
      },
      {
        "title": "Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/agios-pharmaceuticals-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-price-increase-3600838",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AgiosPharmaceut_technicaldot_3600838.png",
        "date": "2025-10-07 19:16:25",
        "description": "Agios Pharmaceuticals has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $40.89, has shown significant volatility over the past year. Despite mixed short-term signals, Agios has outperformed the S&P 500 in various timeframes, reflecting its resilience and commitment to growth."
      },
      {
        "title": "Is Agios Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-agios-pharmaceuticals-inc-technically-bullish-or-bearish-3598983",
        "imagepath": "",
        "date": "2025-10-07 12:15:09",
        "description": "As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, and the monthly RSI is also bullish, indicating strong momentum. Bollinger Bands are bullish on both weekly and monthly time frames, further supporting the bullish stance. Daily moving averages are bullish as well. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, and Dow Theory indicates a mildly bullish trend on a monthly basis. \n\nIn terms of performance, Agios has outperformed the S&P 500 over the past week and month, with returns of 4.13% and 13.55% respectively, compared to 1.09% and 4.15% for the index. However, over the longer term, the stock has underperformed the S&P 500 on a 1-year, 3-year, 5-year, and 10-year basis. Overall, the current technical stance is bullish, with strong indicators ..."
      },
      {
        "title": "Is Agios Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-agios-pharmaceuticals-inc-technically-bullish-or-bearish-3593706",
        "imagepath": "",
        "date": "2025-10-06 12:05:18",
        "description": "As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and the monthly RSI is also bullish, indicating strong momentum. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames, and daily moving averages confirm a bullish stance. However, the KST is mildly bearish on both weekly and monthly charts, and the weekly Dow Theory shows a mildly bullish signal. \n\nIn terms of performance, Agios has outperformed the S&P 500 on a year-to-date basis with a return of 23.25% compared to the S&P 500's 14.18%, but it has underperformed over the 1-year, 3-year, and 5-year periods. Overall, the current technical stance is bullish, supported by strong momentum indicators, despite some mixed signals from KST and Dow Theory...."
      },
      {
        "title": "Is Agios Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-agios-pharmaceuticals-inc-technically-bullish-or-bearish-3591778",
        "imagepath": "",
        "date": "2025-10-05 11:50:12",
        "description": "As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, and the monthly RSI is also bullish, indicating strong upward momentum. Bollinger Bands are bullish on both time frames, supporting the bullish stance. Daily moving averages are bullish as well. However, the KST is mildly bearish on both weekly and monthly, and the weekly OBV is mildly bearish, suggesting some caution. \n\nIn terms of performance, Agios has outperformed the S&P 500 in the year-to-date period with a return of 23.25% compared to 14.18%, but it has underperformed over the 1-year, 3-year, and 5-year periods. Overall, the current technical stance is bullish, reflecting a strong positive trend despite some mixed signals in certain indicators...."
      },
      {
        "title": "Agios Pharmaceuticals Hits Day High with 9.64% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/agios-pharmaceuticals-hits-day-high-with-964-surge-in-stock-price-3585882",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AgiosPharmaceut_priceRelatedfactors_3585882.png",
        "date": "2025-10-01 16:14:24",
        "description": "Agios Pharmaceuticals, Inc. saw a notable increase in stock performance on September 30, 2025, reaching an intraday high. While the company has outperformed the S&P 500 in the short term, it faces long-term challenges, including declining net sales and low profitability metrics."
      }
    ],
    "total": 17,
    "sid": "1149899",
    "stock_news_url": "https://www.marketsmojo.com/news/agios-pharmaceuticals-inc-1149899"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-21 12:05:35

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has changed from very attractive to attractive, indicating a shift in market perception. The company appears to be undervalued, with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA ratio of -3.81, which suggests that the stock may be trading at a significant discount relative to its earnings potential. In comparison to its peers, Agios has a lower P/E ratio than PTC Therapeutics, Inc. at 5.85 and Crinetics Pharmaceuticals, Inc. at -8.95, indicating that it is relatively cheaper in terms of earnings. The company's return performance shows a 1-week return of 4.24% compared to the S&P 500's 1.70%, and a year-to-date return of 28.82% against the S&P 500's 13.30%, which reinforces the notion that the stock may be undervalued....

Agios Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-20 15:22:08

Agios Pharmaceuticals, Inc. has adjusted its valuation, showcasing a low P/E ratio of 4 and a price-to-book value of 1.73. Despite a challenging year, the company has demonstrated resilience with a year-to-date return of 28.82%, outperforming the S&P 500, and maintains a competitive PEG ratio of 0.01.

Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-20 12:23:01

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. Based on the current metrics, the company appears to be undervalued, particularly highlighted by a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81. In comparison to its peers, Agios Pharmaceuticals has a significantly lower P/E ratio than PTC Therapeutics, Inc., which stands at 5.85, and a much lower EV to EBITDA than Supernus Pharmaceuticals, Inc., which is at 13.83. While Agios has shown strong short-term performance, with a 1-month return of 16.23% compared to the S&P 500's 0.96%, its longer-term returns have lagged, particularly over the past three years, where it returned 50.37% versus the S&P 500's 81.19%. Overall, the valuation metrics suggest that Agios Pharmaceuticals is currently undervalued relative to its ...

Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

2025-10-19 12:00:35

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has moved from very attractive to attractive. The company appears to be undervalued based on its current metrics, particularly with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81. In comparison to peers, PTC Therapeutics, Inc. has a P/E of 5.85, while Supernus Pharmaceuticals, Inc. is considered expensive with a P/E of 37.12. Despite the recent downgrade in valuation grade, Agios Pharmaceuticals has shown strong short-term performance, with a year-to-date return of 28.82% compared to the S&P 500's 13.30%. However, over the longer term, the stock has underperformed the index, with a 1-year return of -4.10% versus the S&P 500's 14.08%. Overall, the current valuation metrics suggest that Agios Pharmaceuticals is positioned as an attractive investment opportunity....

Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-07 19:16:25

Agios Pharmaceuticals has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $40.89, has shown significant volatility over the past year. Despite mixed short-term signals, Agios has outperformed the S&P 500 in various timeframes, reflecting its resilience and commitment to growth.

Is Agios Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-07 12:15:09

As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, and the monthly RSI is also bullish, indicating strong momentum. Bollinger Bands are bullish on both weekly and monthly time frames, further supporting the bullish stance. Daily moving averages are bullish as well. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, and Dow Theory indicates a mildly bullish trend on a monthly basis. In terms of performance, Agios has outperformed the S&P 500 over the past week and month, with returns of 4.13% and 13.55% respectively, compared to 1.09% and 4.15% for the index. However, over the longer term, the stock has underperformed the S&P 500 on a 1-year, 3-year, 5-year, and 10-year basis. Overall, the current technical stance is bullish, with strong indicators ...

Is Agios Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-06 12:05:18

As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and the monthly RSI is also bullish, indicating strong momentum. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames, and daily moving averages confirm a bullish stance. However, the KST is mildly bearish on both weekly and monthly charts, and the weekly Dow Theory shows a mildly bullish signal. In terms of performance, Agios has outperformed the S&P 500 on a year-to-date basis with a return of 23.25% compared to the S&P 500's 14.18%, but it has underperformed over the 1-year, 3-year, and 5-year periods. Overall, the current technical stance is bullish, supported by strong momentum indicators, despite some mixed signals from KST and Dow Theory....

Is Agios Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-05 11:50:12

As of 3 October 2025, the technical trend for Agios Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, and the monthly RSI is also bullish, indicating strong upward momentum. Bollinger Bands are bullish on both time frames, supporting the bullish stance. Daily moving averages are bullish as well. However, the KST is mildly bearish on both weekly and monthly, and the weekly OBV is mildly bearish, suggesting some caution. In terms of performance, Agios has outperformed the S&P 500 in the year-to-date period with a return of 23.25% compared to 14.18%, but it has underperformed over the 1-year, 3-year, and 5-year periods. Overall, the current technical stance is bullish, reflecting a strong positive trend despite some mixed signals in certain indicators....

Agios Pharmaceuticals Hits Day High with 9.64% Surge in Stock Price

2025-10-01 16:14:24

Agios Pharmaceuticals, Inc. saw a notable increase in stock performance on September 30, 2025, reaching an intraday high. While the company has outperformed the S&P 500 in the short term, it faces long-term challenges, including declining net sales and low profitability metrics.

View All News